Daratumumab in Combination With High-Dose Cytarabine and Amsacrine as an Effective Salvage Therapy and Bridge to Allogeneic Hematopoietic Stem Cell Transplantation for Refractory T-Cell Acute Lymphoblastic Leukemia: A Case Report.
The achievement of a third complete response with the combination of daratumumab, high-dose cytarabine, and amsacrine in an 11-year-old patient with highly aggressive relapsed T-ALL, enabling subsequent allogeneic hematopoietic stem cell transplantation.
Abstract
Patients with refractory or relapsed T-cell acute lymphoblastic leukemia (R/R T-ALL) have dismal outcomes. While immunotherapies are growing opportunities for B-cell ALL, targeted therapies for T-ALL remain limited. The CD38 antigen, steadily expressed on T-ALL blasts, represents a relevant therapeutic target. Daratumumab, an anti-CD38 monoclonal antibody routinely used in other hematologic malignancies, could be a promising treatment option for T-ALL. We report here the achievement of a third complete response with the combination of daratumumab, high-dose cytarabine (18 g/m2), and amsacrine in an 11-year-old patient with highly aggressive relapsed T-ALL, enabling subsequent allogeneic hematopoietic stem cell transplantation.
An induction regimen based on azacitidine, venetoclax, and dasatinib may represent a safe and effective therapeutic strategy for adult patients with Ph+, bilineal MPAL, particularly when augmented with agents targeting distinct lineage components.
Juan Zhang, Yan Huang, Liang-Kui Luo et al.· Frontiers in Medicine· 0 citations
XmAb18968 is safe and tolerable with encouraging preliminary efficacy, supporting further investigation of CD38 targeting therapies in this setting, and further investigation of CD38 targeting therapies in this setting is supported.
G. S. Guru Murthy, B. Shah, Talha Badar et al.· Leukemia· 0 citations
Therapy-related acute lymphoblastic leukemia (t-ALL) is a rare but increasingly recognized complication of cytotoxic therapy. We report a case of TP53-mutated precursor B-cell acute lymphoblastic leukemia arising in a patient with multiple myeloma treated with CyBorD induction, autologous stem cell transplantation, and...
Ashish Rajput· Global Journal of Medical an...· 0 citations
Background T-cell acute lymphoblastic leukemia (T-ALL) with ABL1 rearrangement is an extremely rare disease, and its clinical significance has not been precisely defined. We report the clinical characteristics of a pediatric patient with T-cell acute lymphoblastic leukemia harboring ABL1 rearrangement and the treatment...
Ming-Yan Zhong, Wen-Ting He, Ling-Ji Zeng et al.· Frontiers in Oncology· 0 citations
CD123-directed CAR T-cell therapy is feasible and demonstrates a favorable safety profile in patients with r/r AML and BPDCN, including those with prior alloHCT, according to a phase 1 trial evaluating CD123-targeting chimeric antigen receptor (CAR) T cells in patients with relapsed/refractory AML.
L. Budde, M. D. Del Real, J. Song et al.· Journal of Hematology & Onco...· 0 citations
The unmet needs in patients with high-risk disease and the challenges of sequencing these therapeutic strategies are discussed, while providing expert clinical practice recommendations to optimize patient outcomes are provided.
P. Caimi, Romano Danesi, G. Iacoboni et al.· Blood reviews· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
